Comparative Evaluation of the Efficacy and Safety of Brimonidine Generics in Glaucoma Therapy
Glaucoma is a chronic neurodegenerative disease that eventually leads to irreversible blindness. The main risk factor for the development and progression of glaucoma is elevated IOP. In cases where the use of prostaglandin analogues is limited, brimonidine is the most rational choice as initial ther...
Saved in:
| Main Authors: | A. A. Antonov, A. A. Vitkov, I. V. Kozlova, A. A. Komarov, E. D. Semenov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ophthalmology Publishing Group
2023-12-01
|
| Series: | Oftalʹmologiâ |
| Subjects: | |
| Online Access: | https://www.ophthalmojournal.com/opht/article/view/2248 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of 0.1 % brimonidine as a starting monotherapy and when added to combination therapy of glaucoma
by: E. D. Semenov, et al.
Published: (2024-12-01) -
New Opportunities in Non-Preservative Glaucoma Therapy
by: A. A. Antonov, et al.
Published: (2021-07-01) -
Changes in the ocular surface condition during the transition to preservative-free hypotensive combination therapy in the long-term observation of patients with advanced stages of glaucoma
by: Dmitry A. Dorofeev, et al.
Published: (2025-03-01) -
To the question about rational choice between original and generic drugs: arguments to use the first
by: N. S. Khodzhaev, et al.
Published: (2019-06-01) -
Some questions about the state of the eye surface in patients before cataract surgery
by: N. S. Lutsenko, et al.
Published: (2020-09-01)